ArticleScientific reports2025
Repurposing FDA-approved drugs and natural compounds to inhibit the RNA-dependent RNA polymerase domain of dengue virus 2 or dengue virus 3.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Precision repurposing of clinically characterized molecules targeting dengue virus RNA-dependent RNA polymerase: an in silico identification and in vitro validation.Folia microbiologica · 2026Article
- Computational discovery of DENV-3 RdRp allosteric inhibitors: biological evaluation and mechanistic studies.Molecular diversity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dengue virus, a member of the arbovirus family, can cause a variety of clinical symptoms. However, there are currently no Food and Drug Administration-approved drugs are currently available for its treatment. We have used RNA-dependent RNA polymerase to identify drug candidates against dengue virus 2 or dengue virus 3. The Smina molecular docking program was used to screen natural compounds and FDA-approved drugs. This study used the pkCSM web server for pharmacokinetic profiling, OSIRIS Data Warrior for physicochemical property assessment, Data Warrior software for cytotoxicity profiling, and molecular dynamics simulations to evaluate the stability of ligand-RdRp interactions. Specifically, the drugs and compounds with the highest negative binding energy and most hydrogen bonds are chlorthalidone, valdecoxib, and ZINC14824819, which interact with the RdRp domain of dengue virus 2, and empagliflozin, netarsudil, and ZINC13375652, which interact with the RdRp domain of dengue virus 3. We propose several FDA-approved drugs and natural compounds that can bind to the RdRp of dengue virus serotypes 2 and 3 and prevent the virus from infecting cells. These compounds show a high level of safety and strong skin and intestinal absorption. Further in vitro and in vivo testing is needed to verify these predictions and assess therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.